Skip to contentN
Nutra Pharma Corp
N
NPHCNutra Pharma Corp Q2 2022 · 10-Q
Revenue$28.43K$28.43K−6.7% vs Q2 2021 Net Income-$645.80K-$645.80KN/M vs Q2 2021 EPS Diluted$0.00$0.00— vs Q2 2021 Gross Profit$29,581+37.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nutra Pharma Corp · CIK 1119643 · Engraved from SEC EDGAR
Operating Cash Flowderived-$284,825N/M Free Cash Flowderived-$284,825N/M Margins · derivedGross margin104.0%+33.6 pt vs Q2 2021
Operating margin-1199.7%+240.6 pt vs Q2 2021
Net margin-2271.5%
ended Jun 30, 2022 · filed Aug 22, 2022 · 53 d after period end